Stada Grows In Russia And CIS With Takeda Deal
Stada To Pay $660m For 20 OTC And Prescription Brands
Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
You may also be interested in...
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Stada’s owner has revealed plans to squeeze out the German firm’s remaining minority shareholders.
Stada has announced the appointment of former Sandoz Germany head Stephan Eder to lead its business in Russia and the CIS. The appointment comes as Stada has just closed a $660m consumer healthcare acquisition with Takeda in the region.